These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17952109)

  • 1. CB2 receptors as new therapeutic targets for liver diseases.
    Lotersztajn S; Teixeira-Clerc F; Julien B; Deveaux V; Ichigotani Y; Manin S; Tran-Van-Nhieu J; Karsak M; Zimmer A; Mallat A
    Br J Pharmacol; 2008 Jan; 153(2):286-9. PubMed ID: 17952109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cannabinoids in chronic liver diseases.
    Parfieniuk A; Flisiak R
    World J Gastroenterol; 2008 Oct; 14(40):6109-14. PubMed ID: 18985799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic expression of cannabinoid receptors CB1 and CB2 correlate with fibrogenesis in patients with chronic hepatitis B.
    Dai E; Zhang L; Ye L; Wan S; Feng L; Qi Q; Yao F; Li Z
    Int J Infect Dis; 2017 Jun; 59():124-130. PubMed ID: 28315398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid signaling and liver therapeutics.
    Mallat A; Teixeira-Clerc F; Lotersztajn S
    J Hepatol; 2013 Oct; 59(4):891-6. PubMed ID: 23567085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The endocannabinoid system as a novel target for the treatment of liver fibrosis].
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Hezode C; Mallat A; Lotersztajn S
    Pathol Biol (Paris); 2008 Feb; 56(1):36-8. PubMed ID: 17412522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.
    Mallat A; Teixeira-Clerc F; Deveaux V; Lotersztajn S
    Expert Opin Ther Targets; 2007 Mar; 11(3):403-9. PubMed ID: 17298297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological actions of cannabinoids.
    Pertwee RG
    Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifibrogenic role of the cannabinoid receptor CB2 in the liver.
    Julien B; Grenard P; Teixeira-Clerc F; Van Nhieu JT; Li L; Karsak M; Zimmer A; Mallat A; Lotersztajn S
    Gastroenterology; 2005 Mar; 128(3):742-55. PubMed ID: 15765409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the endocannabinoid system in liver diseases.
    Caraceni P; Domenicali M; Giannone F; Bernardi M
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):65-77. PubMed ID: 19285261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocannabinoids as novel mediators of liver diseases.
    Mallat A; Lotersztajn S
    J Endocrinol Invest; 2006; 29(3 Suppl):58-65. PubMed ID: 16751709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats.
    Muñoz-Luque J; Ros J; Fernández-Varo G; Tugues S; Morales-Ruiz M; Alvarez CE; Friedman SL; Arroyo V; Jiménez W
    J Pharmacol Exp Ther; 2008 Feb; 324(2):475-83. PubMed ID: 18029545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential hepatoprotective role of the cannabinoid CB
    Rivera P; Vargas A; Pastor A; Boronat A; López-Gambero AJ; Sánchez-Marín L; Medina-Vera D; Serrano A; Pavón FJ; de la Torre R; Agirregoitia E; Lucena MI; Rodríguez de Fonseca F; Decara J; Suárez J
    Br J Pharmacol; 2020 Jul; 177(14):3309-3326. PubMed ID: 32167157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors.
    Gertsch J; Raduner S; Altmann KH
    J Recept Signal Transduct Res; 2006; 26(5-6):709-30. PubMed ID: 17118807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Li L; Serriere-Lanneau V; Ledent C; Mallat A; Lotersztajn S
    Nat Med; 2006 Jun; 12(6):671-6. PubMed ID: 16715087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid-sensitive receptors in cardiac physiology and ischaemia.
    Puhl SL
    Biochim Biophys Acta Mol Cell Res; 2020 Mar; 1867(3):118462. PubMed ID: 30890410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective cannabinoid receptor 2 modulators: a patent review 2009--present.
    Riether D
    Expert Opin Ther Pat; 2012 May; 22(5):495-510. PubMed ID: 22537079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.
    Guindon J; Hohmann AG
    Br J Pharmacol; 2008 Jan; 153(2):319-34. PubMed ID: 17994113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Endocannabinoids: therapeutic perspectives in chronic liver diseases].
    Lotersztajn S; Teixeira-Clerc F; Hezode C; Tran van Nhieu J; Deveaux V; Mallat A
    Gastroenterol Clin Biol; 2007 Mar; 31(3):255-8. PubMed ID: 17396081
    [No Abstract]   [Full Text] [Related]  

  • 20. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
    Pertwee RG
    Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.